N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement

N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.

We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.

Inclusion Criteria:

• patients with rheumatic heart disease undergoing single valve replacement

Exclusion Criteria:

• End stage renal disease (plasma creatinine concentration ≥ 300 µmol/L)
• Emergency cardiac surgery
• Planned off-pump cardiac surgery
• Chronic inflammatory disease on immunosuppression
• Chronic moderate to high dose corticosteroid therapy (≥ 10 mg/day prednisone or equivalent)
• Age ≤ 18 years.